title: [Antiestrogen therapy in the treatment of breast neoplasms].
abstract: During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion. Some studies compare or associate classic AE with the new SERMs and AI, both in adjuvant therapy and in treatment for advanced forms. Other trials assess the anti-osteoporotic activity of some SERMs which present concomitant inhibitory activity on the breast and endometrium.
authors.affiliation: Dipartimenti di Discipline Ginecologiche ed Ostetriche Cattedra B, Università degli Studi, Turin, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Alba
authors.forename: G
authors.initials: G
authors.lastname: Ragonesi
authors.forename: F
authors.initials: F
authors.lastname: Colla
authors.forename: A
authors.initials: A
authors.lastname: Mazzoleni
authors.forename: C
authors.initials: C
authors.lastname: Farina
mesh_terms: D000328:Adult; D000077384:Anastrozole; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005544:Forecasting; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077289:Letrozole; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use; D010024:Osteoporosis / Q000517:prevention & control; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use*; D013629:Tamoxifen / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017312:Toremifene / Q000008:administration & dosage / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D007211:Indoles; D009570:Nitriles; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; C038345:droloxifene; C064635:TAT 59; C041791:zindoxifene; D000077384:Anastrozole; C071362:idoxifene; D020849:Raloxifene Hydrochloride; D000077289:Letrozole; D017312:Toremifene
vernacular_title: La terapia antiestrogenica nel trattamento del carcinoma della mammella.